Jasper Therapeutics (JSPR) to Post Quarterly Earnings on Wednesday

Posted by George Bondi on Aug 5th, 2026

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Jasper Therapeutics to post earnings of ($0.38) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, analysts expect Jasper Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $0.67 on Wednesday. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $3.14. The firm has a market capitalization of $18.76 million, a P/E ratio of -0.21 and a beta of 3.02. The company’s 50 day moving average price is $0.58 and its two-hundred day moving average price is $0.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Finally, Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Get Our Latest Analysis on Jasper Therapeutics

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its position in shares of Jasper Therapeutics by 6,394.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after acquiring an additional 1,719,602 shares during the last quarter. Acorn Capital Advisors LLC acquired a new position in shares of Jasper Therapeutics in the 3rd quarter worth approximately $3,291,000. Velan Capital Investment Management LP boosted its stake in shares of Jasper Therapeutics by 86.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after purchasing an additional 1,234,567 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Jasper Therapeutics during the third quarter worth $2,475,000. Finally, Millennium Management LLC raised its stake in Jasper Therapeutics by 194.2% during the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after buying an additional 708,844 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.